Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of ALNY would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (2004) — listing | $375,227 11.3× | $545,051 11.3× |
| Year 6 (2009) | $208,779 7.9× | $303,176 7.9× |
| Year 11 (2014) | $51,782 2.8× | $75,050 2.8× |
| Year 16 (2019) | $21,350 1.9× | $31,014 1.9× |
| Year 21 (2024) | $4,292 1.2× | $6,285 1.2× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Headquarters
Cambridge, Massachusetts, United States
Popular scenarios with ALNY
For illustration only — not investment advice. Past performance is not indicative of future results.